Sintx Technologies Inc Stock Price, News & Analysis

SINTX Technologies reported preliminary Q3 2021 revenue of approximately $240k, surpassing Q1 and Q2 revenues. Revenue stems from three sectors: spinal implants, antipathogenic fabrics, and armor. The company anticipates new revenue in Q4 2021 from open prototype orders for aerospace components and industrial applications. SINTX is focused on expanding its presence in advanced ceramics manufacturing at its FDA and ISO certified facility. A detailed business update will follow the upcoming Quarterly Report on Form 10-Q.

SINTX Technologies, Inc. (NASDAQ: SINT) announced the shipment of production quantities of a new porous, laser-textured monolithic silicon nitride implant for surgical spinal solutions. This shipment follows successful collaboration with CTL Amedica and supports a product launch expected in Q4 2021. The implants aim to enhance osseointegrative and antibacterial properties. SINTX has also submitted a provisional patent for improved manufacturing methods, supported by a Phase 1 grant from NIH. The company is actively investing in advanced manufacturing technologies and workforce recruitment.

SINTX Technologies has been awarded a $308,301 Phase 1 grant by the NIH to develop a 3-D printed silicon nitride – polyetheretherketone (SN-PEEK) spinal implant. This research focuses on enhancing the antibacterial and osseointegrative properties of silicon nitride. The project aims to capitalize on existing PEEK implant technology while integrating novel characteristics. Collaborating with notable universities, SINTX is positioned to advance spinal implant technology and plans to pursue a Phase 2 grant upon completion of this project.

SINTX Technologies held its annual meeting of stockholders on September 15, 2021, which was adjourned due to a lack of quorum. A majority of the outstanding shares entitled to vote was not present. The meeting is now rescheduled for October 13, 2021, at 10:30 a.m. MT. Stockholders of record as of July 26, 2021, are urged to vote by October 12, 2021. Approximately 44% of shares represented by proxies had been submitted. The company plans to further solicit votes and may incur additional costs if a quorum is not achieved at the adjourned meeting.

SINTX Technologies has established a new subsidiary, SINTX Armor, based in Salt Lake City, Utah, with plans to operate by the end of 2021. The company signed a decade-long lease for a facility that will focus on developing and manufacturing advanced ceramic armor, including boron carbide torso plates. This move aims to capture a share of the U.S. Department of Defense and law enforcement markets. SINTX has already shipped its first prototype order and aims to enhance innovation and operational efficiency in armor production.

SINTX Technologies announced the hiring of Joseph Palomo as Vice President of Business Development for its antipathogenic segment. The company is focusing on expanding its capabilities in manufacturing antipathogenic silicon nitride powders, with the AP² and AP⁴ grades showing enhanced efficacy against pathogens, including SARS-CoV-2 variants. SINTX is pursuing U.S. EPA registration and has collaborations in place with European firms and universities. Additionally, ongoing research confirms silicon nitride's effectiveness in neutralizing various viruses, positioning SINTX for growth in protective textile applications.

SINTX Technologies (NASDAQ: SINT) has announced a reassessment of its exclusive Patent License Agreement with O2TODAY after O2TODAY revealed regulatory hurdles delaying the launch of its SiNPRO filters and masks. O2TODAY is refunding pre-orders due to these issues. SINTX is now considering a return to initial joint development efforts with O2TODAY as it seeks alternative routes to market its antipathogenic facemask technology. This is part of SINTX's broader strategy to develop various medical applications using silicon nitride.

SINTX Technologies announced the first shipment of its new FleX SN-PEEK product, launched on July 20, 2021, designed for orthopedic implants. This innovative composite material combines the bioactivity of silicon nitride with the established properties of Zeniva PEEK, enhancing bone healing and infection resistance. The product aims to improve surgical outcomes across various applications, including spine surgery and joint replacements. SINTX continues to expand its customer base in the biomedical market, leveraging its expertise in manufacturing silicon nitride ceramics.

SINTX Technologies (NASDAQ: SINT) announced the acquisition of equipment and processes from B4C, LLC for manufacturing ballistic armor plates. Additionally, SINTX signed a technology license with Precision Ceramics USA Inc. to create a ceramic composite for defense applications. The new subsidiary, SINTX Armor, aims to produce high-strength Boron Carbide and a cost-effective Boron Carbide-Silicon Carbide composite. This move diversifies SINTX’s product offerings into military and law enforcement markets, addressing growing demand for advanced armor solutions.